Detroit R&D, Inc. Company Profile

Background

Overview

Detroit R&D, Inc. is a biotechnology company founded in 1997 by Dr. Hyesook Kim. The company specializes in the development and manufacture of diagnostic and drug-screening products, focusing on cardiovascular diseases, cancer, and environmental health. Its laboratories and offices are situated in downtown Detroit, Michigan.

Mission and Vision

Detroit R&D's mission is to contribute to society by developing leading-edge technologies, providing in-depth customer services, and partnering in the improvement of Detroit. The company aims to build trust with the research community by offering high-quality products through innovative technology.

Industry Significance

Detroit R&D has established itself as a significant player in the biotechnology sector, particularly in the fields of hypertension, stroke, cardiovascular diseases, diabetes, and cancer diagnostics. Its products are utilized by researchers worldwide, contributing to advancements in medical diagnostics and treatment.

Key Strategic Focus

Core Objectives

The company's primary objectives include the development of novel diagnostic assays, advancement of drug-screening technologies, and fostering collaborations to enhance research capabilities.

Areas of Specialization

Detroit R&D specializes in:

Hypertension and stroke diagnostics

Cardiovascular diseases and diabetes

Cancer biomarkers for prostate, breast, and lung cancers

Environmental estrogens such as BPA and BPS

COX-2 biomarkers

Cytochromes P450 (CYPs)

Oxidative stress

Mitochondrial DNA damage and copy number

Glycosylated c-myc, p53, and NF-kB

Glycan microarrays

Wound healing

Label-free nanotechnology

Key Technologies Utilized

The company employs advanced technologies such as enzyme-linked immunosorbent assays (ELISA), antibody microarrays, and label-free nanotechnology to develop its diagnostic and drug-screening products.

Primary Markets Targeted

Detroit R&D targets markets in medical research, diagnostics, and pharmaceutical development, focusing on cardiovascular diseases, cancer, and environmental health.

Financials and Funding

Funding History

Detroit R&D has secured multiple funding awards from the National Institutes of Health (NIH), including 18 Small Business Innovation Research (SBIR) Phase I and II awards totaling over $10 million. These funds have been utilized to develop hypertension diagnostics, mitochondrial DNA damage assays, cancer microarrays, and glycosylated biomarkers for various cancers.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The capital raised has been primarily used for research and development of diagnostic assays, drug-screening technologies, and to support the company's operational expenses.

Pipeline Development

Key Pipeline Candidates

Detroit R&D is developing:

Hypertension Diagnostics: Novel blood and urine biomarkers for hypertension detection.

Cancer Biomarkers: Diagnostic assays for prostate, breast, and lung cancers.

Environmental Estrogens: Detection assays for BPA and BPS.

Stages of Development

The company has advanced these candidates through various stages, including preclinical development and validation studies. Specific timelines for anticipated milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Detroit R&D has developed proprietary technologies in:

Hypertension diagnostics

Cancer biomarker assays

Environmental estrogen detection

Cytochrome P450 assays

Oxidative stress measurement

Mitochondrial DNA analysis

Glycan microarrays

Wound healing assays

Label-free nanotechnology

Significant Scientific Methods

The company employs scientific methods such as enzyme-linked immunosorbent assays (ELISA), antibody microarrays, and label-free nanotechnology to develop its diagnostic and drug-screening products.

Leadership Team

Key Executives

Dr. Hyesook Kim: Director of Research and President. Dr. Kim founded Detroit R&D in 1997 and has been instrumental in its growth and development.

Dr. Aby Joiakim: Assistant Director of Research. Dr. Joiakim contributes to the company's research initiatives and development strategies.

Dr. Julia Santos: Senior Scientist. Dr. Santos plays a key role in the company's scientific research and product development.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in diagnostics and drug screening, is highly competitive, with numerous companies developing similar products. The market is characterized by rapid technological advancements and a strong emphasis on research and development.

Competitor Analysis

Key competitors include:

Everest Medical: Specializes in medical diagnostics and laboratory equipment.

Ziath: Provides sample management solutions for laboratories.

Dutscher: Offers laboratory equipment and consumables.

Strategic Collaborations and Partnerships

In 2012, Detroit R&D entered into a distribution agreement with ALPCO Diagnostics to expand the reach of its hypertension and oxidative stress products in North America.

Operational Insights

Detroit R&D's strategic location in Detroit, Michigan, places it within a region renowned for its automotive and biomedical research, providing access to a skilled workforce and potential collaborative opportunities.

Strategic Opportunities and Future Directions

The company aims to leverage its proprietary technologies to expand its product offerings, enhance research capabilities, and explore new markets in diagnostics and drug development.